CME

Host: Neal Bhatia, MD, FAAD Guest: Joshua Grosshandler, MD, FAAD In the sixth installment of this six-part series, Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Joshua Grosshandler, MD, FAAD, speculate about normalization of pigment as a potential benefit of aryl hydrocarbon receptor agonism.

Host: Neal Bhatia, MD, FAAD Guest: Joshua Grosshandler, MD, FAAD In the fifth installment of this six-part series, Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Joshua Grosshandler, MD, FAAD, talk about the challenges involved with setting treatment goals with inflammatory dermatoses.

Host: Neal Bhatia, MD, FAAD Guest: Joshua Grosshandler, MD, FAAD In the fourth installment of this six-part series, Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Joshua Grosshandler, MD, FAAD, discuss how topical therapies can be used to control inflammation and how to talk about that with patients.

Host: Neal Bhatia, MD, FAAD Guest: Joshua Grosshandler, MD, FAAD In the third installment of this six-part series, Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Joshua Grosshandler, MD, FAAD, describe the importance of skin barrier maintenance in treating inflammatory dermatoses.

Host: Neal Bhatia, MD, FAAD Guest: Joshua Grosshandler, MD, FAAD In the second installment of this six-part series, Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Joshua Grosshandler, MD, FAAD, explain how tapinarof fits in the armamentarium for treating inflammatory dermatoses.

Host: Neal Bhatia, MD, FAAD Guest: Joshua Grosshandler, MD, FAAD In the first installment of this six-part series, Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Joshua Grosshandler, MD, FAAD, discuss the aryl hydrocarbon receptor (AhR) pathway and how AhR agonists work.

Faculty: Carolyn Lam, MD, PhD Faculty: Stephen J. Greene, MD Using a real-world patient case, Dr. Stephen Greene and Dr. Carolyn Lam explore strategies to optimize care for patients with heart failure with reduced ejection fraction (HFrEF) who remain at elevated risk despite guideline-directed medical therapy (GDMT). The discussion examines the importance of avoiding clinical inertia, addressing p...

Faculty: Federico Alberici, MD, PhD Faculty: Anastasia Liossatou, PhD, RN Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies...

Faculty: Federico Alberici, MD, PhD Faculty: Anastasia Liossatou, PhD, RN Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies...

Faculty: Federico Alberici, MD, PhD Faculty: Anastasia Liossatou, PhD, RN Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies...

Faculty: Federico Alberici, MD, PhD Faculty: Anastasia Liossatou, PhD, RN Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies...

Faculty: Nancy Helou, PhD Faculty: Steven Fishbane, MD Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recogni...

Faculty: Steven Fishbane, MD Faculty: Nancy Helou, PhD Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recogni...

Faculty: Steven Fishbane, MD Faculty: Nancy Helou, PhD Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recogni...

Faculty: Steven Fishbane, MD Faculty: Nancy Helou, PhD Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recogni...

Faculty: Federico Alberici, MD, PhD Faculty: Anastasia Liossatou, PhD, RN Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies...

Faculty: Ravi Savarirayan, MBBS, MD Faculty: Julie Hoover-Fong, MD, PhD, FACMGG In this expert discussion, Drs. Ravi Savarirayan and Julie Hoover-Fong examine how findings from the PROPEL 3 trial of oral infigratinib fit within the evolving treatment landscape for achondroplasia in children. They review the study's efficacy and safety results in the context of currently available therapies and dis...

Faculty: Amer Zeidan, MBBS, MHS Faculty: Ghayas Issa, MD, MS This chapterized expert interview examines six common clinical decision points encountered when incorporating menin inhibitors into the management of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). Faculty discuss evidence-informed approaches to treatment initiation, monitoring strategies, drug-drug interaction management,...

Faculty: Kathleen N. Moore, MD Faculty: Ritu Salani, MD This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection a...

Faculty: Kathleen N. Moore, MD Faculty: Ritu Salani, MD This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection a...

Faculty: Kathleen N. Moore, MD Faculty: Ritu Salani, MD This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection a...

Faculty: Kathleen N. Moore, MD Faculty: Ritu Salani, MD This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection a...

Faculty: Kathleen N. Moore, MD Faculty: Ritu Salani, MD This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection a...

Host: Alex F. Herrera, MD This online activity is designed to provide the healthcare team with the latest developments and critical insights into Hodgkin lymphoma treatment. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application. This online education activity will...

Faculty: Michael A. Levine, MD, ML, MACE Faculty: Aliya Khan, MD, FRCPC, FACP, FACE, FASBMR In this expert discussion, Drs. Michael Levine and Aliya Khan review emerging evidence in autosomal dominant hypocalcemia type 1 (ADH1), including findings from the CALIBRATE trial presented at ENDO 2026. They discuss how CaSR-targeted therapy with encaleret may address the underlying disease mechanism and...